- Titel
- PLOD Family: A Novel Biomarker for Prognosis and Personalized Treatment in Soft Tissue Sarcoma
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:15-qucosa2-859060
- Quellenangabe
- Genes
Erscheinungsjahr: 2022
Jahrgang: 13
Heft: 5
E-ISSN: 2073-4425
Artikelnummer: 787 - Erstveröffentlichung
- 2022
- Abstract (EN)
- Despite various treatment attempts, the heterogenous group of soft tissue sarcomata (STS) with more than 100 subtypes still shows poor outcomes. Therefore, effective biomarkers for prognosis prediction and personalized treatment are of high importance. The Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase (PLOD) gene family, which is related to multiple cancer entities, consists of three members which encode important enzymes for the formation of connective tissue. The relation to STS, however, has not yet been explored. In this study, data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were used to analyze the role of PLOD1–3 in STS. It was found that an overexpression of PLOD family members correlates with poor prognosis, which might be due to an increased infiltration of immune-related cells in the tumor microenvironment. In STS, the expression of PLOD genes could be a novel biomarker for prognosis and a personalized, more aggressive treatment in these patients.
- Andere Ausgabe
- Link zur Erstveröffentlichung
Link: https://doi.org/10.3390/genes13050787 - Freie Schlagwörter (EN)
- PLOD family; soft tissue sarcoma; prognostic; tumor microenvironment; immune infiltration; personalized treatment
- Klassifikation (DDC)
- 570
- Verlag
- MDPI, Basel
- Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:15-qucosa2-859060
- Veröffentlichungsdatum Qucosa
- 09.06.2023
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
CC BY 4.0